{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:41:26Z","timestamp":1791484886924,"version":"4.3.4"},"reference-count":33,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T00:00:00Z","timestamp":1366934400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2014,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Despite acne persisting into adulthood in up to 50% of the population, very few therapeutic studies have been performed in this age group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>To assess the efficacy of 5\u00a0mg\/day isotretinoin in adult acne.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An investigator initiated, industry\u2010sponsored, randomized, double\u2010blind, placebo\u2010controlled, parallel\u2010group clinical study of isotretinoin 5\u00a0mg\/day in the treatment of low\u2010grade adult acne for 16\u00a0weeks followed by an open\u2010label phase of 16\u00a0weeks. Group 1 received 32\u00a0weeks of 5\u00a0mg isotretinoin\/day; Group 2 first received 16\u00a0weeks of placebo, followed by 16 weeks open\u2010label 5\u00a0mg isotretinoin\/day. Patients were followed for a further 10 weeks off treatment. The primary end\u2010point was the difference in acne lesion count and disability score after 16 weeks isotretinoin compared to placebo. Secondary end\u2010points included differences in these counts\/scores after 32\u00a0weeks of isotretinoin compared to baseline, and after 10 weeks off treatment, compared to end of treatment (week 32).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There were highly significant differences (<jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.0001) in acne lesion count, Dermatology Life Quality Index and self\u2010assessment after 16\u00a0weeks of isotretinoin, compared to placebo (both per protocol and intention to treat). Acne lesions fell significantly, within 4\u00a0weeks of 5\u00a0mg isotretinoin\/day (Group 1) and continued to fall during 32\u00a0weeks of treatment [acne lesion count (mean\u00a0\u00b1\u00a0SD): 11.3\u00a0\u00b1\u00a08.1 (baseline), 3.6\u00a0\u00b1\u00a05.5 (week 16), 1.3\u00a0\u00b1\u00a03.1 (week 32), <jats:italic>P\u00a0<\/jats:italic>&lt;\u00a00.0001)]. There was a similar significant reduction in acne lesion count in Group 2, but only from week 20, 4\u00a0weeks after starting open\u2010label 5\u00a0mg isotretinoin. Adverse effects were minimal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Isotretinoin 5\u00a0mg\/day is effective in reducing the number of acne lesions, and improving patients dermatologic quality of life, with minimal adverse effects.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.12170","type":"journal-article","created":{"date-parts":[[2013,4,26]],"date-time":"2013-04-26T10:42:05Z","timestamp":1366972925000},"page":"747-754","source":"Crossref","is-referenced-by-count":52,"title":["Isotretinoin 5\u00a0mg daily for low\u2010grade adult acne vulgaris \u2013 a placebo\u2010controlled, randomized double\u2010blind study"],"prefix":"10.1111","volume":"28","author":[{"given":"M.","family":"Rademaker","sequence":"first","affiliation":[{"name":"Dermatology Department Waikato Hospital Hamilton New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.M.","family":"Wishart","sequence":"additional","affiliation":[{"name":"103A Mountain Road, Epsom Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.M.","family":"Birchall","sequence":"additional","affiliation":[{"name":"Auckland Dermatology Auckland New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,4,26]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)80056-5"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.1.6171.1109"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1089\/jwh.2010.2722"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-3083.2001.00357.x"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.06.045"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2010.03813.x"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.11.021"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200809050-00001"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(95)90414-X"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00128071-200607050-00002"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1159\/000246134"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2303.2003.00108.x-i1"},{"key":"e_1_2_6_14_1","first-page":"41","article-title":"Low\u2010dose schema of isotretinoin in acne vulgaris","volume":"23","author":"Mandekou\u2010Lefaki I","year":"2003","journal-title":"Int J Clin Pharmacol Res"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1439-0353.2004.03739.x"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.11.1061"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2010.00657.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1984.tb04020.x"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.1994.tb01167.x"},{"key":"e_1_2_6_20_1","first-page":"1252","article-title":"Persistent acne in adult women","volume":"137","author":"Shaw JC","year":"2001","journal-title":"Arch Dermatol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03099.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(98)70598-5"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1998.02321.x"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.1997.17771864.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2010.10152.x"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2133.2000.03626.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1529-8019.2006.00084.x"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.R100015-JLR200"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.4161\/derm.1.3.8258"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2008.338"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12366092"},{"key":"e_1_2_6_32_1","article-title":"Isotretinoin: dose, duration and relapse. What does 30\u00a0years of usage tell us?","author":"Rademaker M","year":"2012","journal-title":"Australas J Dermatol"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2006.01671.x"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02837.x"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12170","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.12170","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.12170","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:30:07Z","timestamp":1695573007000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.12170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,26]]},"references-count":33,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["10.1111\/jdv.12170"],"URL":"https:\/\/doi.org\/10.1111\/jdv.12170","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,26]]}}}